Literature DB >> 34497107

Are All SGLT2 Inhibitors Created Equal?

L Parker Gregg1,2,3, Sankar D Navaneethan4,2,3,5.   

Abstract

Entities:  

Keywords:  SGLT2 inhibitors; eGFR; kidney disease; sodium-glucose cotransporter-2

Mesh：

Substances：

Year:  2021        PMID： 34497107      PMCID： PMC8729580          DOI： 10.2215/CJN.09720721

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   10.614


× No keyword cloud information.
  11 in total

1.  GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials.

Authors:  Lesley A Inker; Hiddo J L Heerspink; Hocine Tighiouart; Andrew S Levey; Josef Coresh; Ron T Gansevoort; Andrew L Simon; Jian Ying; Gerald J Beck; Christoph Wanner; Jürgen Floege; Philip Kam-Tao Li; Vlado Perkovic; Edward F Vonesh; Tom Greene
Journal:  J Am Soc Nephrol       Date:  2019-07-10       Impact factor: 10.121

2.  Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial.

Authors:  Christoph Wanner; Hiddo J L Heerspink; Bernard Zinman; Silvio E Inzucchi; Audrey Koitka-Weber; Michaela Mattheus; Stefan Hantel; Hans-Juergen Woerle; Uli C Broedl; Maximilian von Eynatten; Per-Henrik Groop
Journal:  J Am Soc Nephrol       Date:  2018-10-12       Impact factor: 10.121

3.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Authors:  Vlado Perkovic; Meg J Jardine; Bruce Neal; Severine Bompoint; Hiddo J L Heerspink; David M Charytan; Robert Edwards; Rajiv Agarwal; George Bakris; Scott Bull; Christopher P Cannon; George Capuano; Pei-Ling Chu; Dick de Zeeuw; Tom Greene; Adeera Levin; Carol Pollock; David C Wheeler; Yshai Yavin; Hong Zhang; Bernard Zinman; Gary Meininger; Barry M Brenner; Kenneth W Mahaffey
Journal:  N Engl J Med       Date:  2019-04-14       Impact factor: 91.245

4.  Ertugliflozin and Slope of Chronic eGFR: Prespecified Analyses from the Randomized VERTIS CV Trial.

Authors:  David Z I Cherney; Francesco Cosentino; Samuel Dagogo-Jack; Darren K McGuire; Richard Pratley; Robert Frederich; Mario Maldonado; Chih-Chin Liu; Jie Liu; Annpey Pong; Christopher P Cannon
Journal:  Clin J Am Soc Nephrol       Date:  2021-06-18       Impact factor: 10.614

5.  Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.

Authors:  Christopher P Cannon; Richard Pratley; Samuel Dagogo-Jack; James Mancuso; Susan Huyck; Urszula Masiukiewicz; Bernard Charbonnel; Robert Frederich; Silvina Gallo; Francesco Cosentino; Weichung J Shih; Ira Gantz; Steven G Terra; David Z I Cherney; Darren K McGuire
Journal:  N Engl J Med       Date:  2020-09-23       Impact factor: 176.079

6.  Dapagliflozin in Patients with Chronic Kidney Disease.

Authors:  Hiddo J L Heerspink; Bergur V Stefánsson; Ricardo Correa-Rotter; Glenn M Chertow; Tom Greene; Fan-Fan Hou; Johannes F E Mann; John J V McMurray; Magnus Lindberg; Peter Rossing; C David Sjöström; Roberto D Toto; Anna-Maria Langkilde; David C Wheeler
Journal:  N Engl J Med       Date:  2020-09-24       Impact factor: 91.245

7.  Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.

Authors:  Vlado Perkovic; Dick de Zeeuw; Kenneth W Mahaffey; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Terrance D Barrett; Michele Weidner-Wells; Hsiaowei Deng; David R Matthews; Bruce Neal
Journal:  Lancet Diabetes Endocrinol       Date:  2018-06-21       Impact factor: 32.069

8.  Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial.

Authors:  David Z I Cherney; Bernard Charbonnel; Francesco Cosentino; Samuel Dagogo-Jack; Darren K McGuire; Richard Pratley; Weichung J Shih; Robert Frederich; Mario Maldonado; Annpey Pong; Christopher P Cannon
Journal:  Diabetologia       Date:  2021-03-04       Impact factor: 10.122

9.  Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.

Authors:  Milton Packer; Stefan D Anker; Javed Butler; Gerasimos Filippatos; Stuart J Pocock; Peter Carson; James Januzzi; Subodh Verma; Hiroyuki Tsutsui; Martina Brueckmann; Waheed Jamal; Karen Kimura; Janet Schnee; Cordula Zeller; Daniel Cotton; Edimar Bocchi; Michael Böhm; Dong-Ju Choi; Vijay Chopra; Eduardo Chuquiure; Nadia Giannetti; Stefan Janssens; Jian Zhang; Jose R Gonzalez Juanatey; Sanjay Kaul; Hans-Peter Brunner-La Rocca; Bela Merkely; Stephen J Nicholls; Sergio Perrone; Ileana Pina; Piotr Ponikowski; Naveed Sattar; Michele Senni; Marie-France Seronde; Jindrich Spinar; Iain Squire; Stefano Taddei; Christoph Wanner; Faiez Zannad
Journal:  N Engl J Med       Date:  2020-08-28       Impact factor: 176.079

10.  Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced.

Authors:  Faiez Zannad; João Pedro Ferreira; Stuart J Pocock; Cordula Zeller; Stefan D Anker; Javed Butler; Gerasimos Filippatos; Sibylle Jenny Hauske; Martina Brueckmann; Egon Pfarr; Janet Schnee; Christoph Wanner; Milton Packer
Journal:  Circulation       Date:  2020-10-23       Impact factor: 29.690
View more
  1 in total

Review 1.  Sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes: Barriers and solutions for improving uptake in routine clinical practice.

Authors:  Kamlesh Khunti; Serge Jabbour; Xavier Cos; Sunder Mudaliar; Christian Mende; Marc Bonaca; Paola Fioretto
Journal:  Diabetes Obes Metab       Date:  2022-03-30       Impact factor: 6.408
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.